Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers shares fall on lung cancer timeline setback

01/20/2017 | 12:20pm EDT
A trader passes by a screen displaying the tickers symbols for Bristol-Myers Squibb and Intelsat, Ltd. on the floor at the New York Stock Exchange

(Reuters) - Shares of Bristol-Myers Squibb (>> Bristol-Myers Squibb Co) fell nearly 10 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co's (>> Merck & Co., Inc.) leading position in the burgeoning immuno-oncolgy field.

(Reuters) - Shares of Bristol-Myers Squibb (>> Bristol-Myers Squibb Co) fell nearly 10 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co's (>> Merck & Co., Inc.) leading position in the burgeoning immuno-oncolgy field.

Lung cancer is by far the biggest oncology market and a handful of companies have been jockeying for position in the battle to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies.

Merck shares rose 3.8 percent to $62.60, while Bristol fell to $50.04.

Bristol-Myers had suggested it would seek a path to swift approval of an Opdivo/Yervoy combination in first-line non-small cell lung cancer (NSCLC) only to reverse course after reviewing available data. The company did not say whether the data was disappointing or merely insufficient to seek accelerated approval.

Cowen and Co analyst Steve Scala downgraded his rating on Bristol shares to "market perform" from "outperform" and lowered his price target on the stock to $65 from $85.

The news followed Merck's surprise announcement last week that it had filed for swift U.S. approval of its Opdivo rival, Keytruda, in combination with chemotherapy in first-line lung cancer, and had received a May 10 regulatory decision date.

"Opdivo sales could be at risk given possible availability of Merck's Keytruda/chemo combo in the second quarter, and there might be more risk in earnings per share given that lung market dynamics are changing quickly," Scala wrote.

Merck will not only likely be first, but said its combination will be less expensive than rival therapies due to the lower cost of older chemotherapy versus combinations that pair immuno-oncolgy drugs.

Bristol, which had been first to market with potentially game-changing drugs that spur the immune system to fight cancer, was long perceived as the industry leader in immuno-oncology, with Merck hot on its heels and AstraZeneca (>> AstraZeneca plc) and Roche (>> Roche Holding Ltd.) playing catch-up.

That changed in August, when Opdivo failed as a monotherapy against first-line lung cancer, where Keytruda succeeded, resetting the immuno-oncology pecking order.

Some analysts said the latest Opdivo setback was good news for AstraZeneca and Roche, allowing them to close the gap on Bristol-Myers.

However, Bernstein analyst Tim Anderson noted that Astra's combination includes a CTLA4 drug similar to Bristol's Yervoy.

"This could have negative implications for AstraZeneca, who similarly has CTLA4 combination at the heart of its IO platform," he wrote.

AstraZeneca shares were off 3.3 percent.

(Reporting by Bill Berkrot; Editing by Tom Brown)

By Bill Berkrot


ę Reuters 2017
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.21% 8296 Delayed Quote.15.78%
BRISTOL-MYERS SQUIBB COMPANY -0.72% 67.9099 Delayed Quote.10.17%
MERCK & CO., INC. -0.48% 77.17 Delayed Quote.-5.21%
NEXT PLC 0.32% 8114 Delayed Quote.14.20%
ROCHE HOLDING AG -1.08% 343.6 Delayed Quote.12.39%
SEEK LIMITED 0.72% 30.6 End-of-day quote.7.26%
All news about ASTRAZENECA PLC
08:52aTHE LATEST : Netherlands bans multi-day summer festivals
AQ
06:41aMixing AstraZeneca, Pfizer-BioNTech COVID-19 Doses Raises Antibodies, South K..
MT
06:18aASTRAZENECA : Opinion based on results from Ultomiris Phase III trial that showe..
PU
05:40aASTRAZENECA : India to miss end-July vaccination target as Bharat Biotech lags
RE
04:57aASTRAZENECA : European Regulator Recommends AstraZeneca's Blood Disorder Drug fo..
MT
03:55aASTRAZENECA : Mixed AstraZeneca-Pfizer shot boosts COVID antibody level - study
RE
03:44aCORONAVIRUS - TUNISIA : Belgium sends emergency aid to Tunisia in the fight agai..
AQ
02:45aASTRAZENECA : EU regulator backs AstraZeneca drug for rare blood disorder in chi..
RE
02:28aAstraZeneca Gets EU Marketing Authorization Recommendation
DJ
02:23aASTRAZENECA : Rare Blood Disease Drug Wins Expanded EU Approval Recommendation
MT
More news
Financials (USD)
Sales 2021 31 752 M - -
Net income 2021 4 669 M - -
Net Debt 2021 10 816 M - -
P/E ratio 2021 33,0x
Yield 2021 2,42%
Capitalization 181 B 181 B -
EV / Sales 2021 6,03x
EV / Sales 2022 5,25x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 116,57 $
Average target price 132,19 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC15.78%155 197
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246